Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease

Journal of Neural Transmission

Volumn 120, Issue 4, 2013, Pages 673-681

  Zádori, Dénes ^a   Szalárdy, Levente ^a   Toldi, József ^b   Fülöp, Ferenc ^b   Klivényi, Péter ^a   Vécsei, László ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Dopaminergic dysfunctioning; Glutamate excitotoxicity; Kynurenines; l DOPA induced dyskinesia; Mental dysfunctioning; Parkinson's disease; Therapy

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; BUNGAROTOXIN RECEPTOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENKEPHALIN; GLUTAMIC ACID; KYNURENIC ACID; KYNURENINE; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID;

CONFERENCE PAPER; DOPAMINERGIC ACTIVITY; DOPAMINERGIC DYSFUNCTIONING; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DYSKINESIA; EXCITOTOXICITY; GENETIC ANALYSIS; GENOTYPE; HUMAN; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; OXIDATIVE STRESS; PARKINSON DISEASE; PLASTICITY; PRIORITY JOURNAL; SUBSTITUTION THERAPY;

BRAIN; DOPAMINE; DOPAMINE AGENTS; GLUTAMIC ACID; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 84875699375     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0930-8     Document Type: Conference Paper

References (102)

1. Acuna-Castroviejo D, Tapias V, Lopez LC, Doerrier C, Camacho E, Carrion MD, Mora F, Espinosa A, Escames G (2011) Protective effects of synthetic kynurenines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Brain Res Bull 85:133-140
2. Betarbet R, Porter RH, Greenamyre JT (2000) GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation. J Neurochem 74:1166-1174 (Pubitemid 30104314)
3. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC Jr, Nairn AC, Greengard P (1999) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402:669-671 (Pubitemid 129516337)
4. Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 196:422-429 (Pubitemid 41607831)
5. Birch PJ, Grossman CJ, Hayes AG (1988) Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur J Pharmacol 151:313-315
6. Blandini F (2010) An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct Neurol 25:65-71
7. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211 (Pubitemid 36007810)
8. Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR (1991) Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 6:133-138
9. Calabresi P, Maj R, Pisani A, Mercuri NB, Bernardi G (1992) Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J Neurosci 12:4224-4233
10. Calabresi P, Saiardi A, Pisani A, Baik JH, Centonze D, Mercuri NB, Bernardi G, Borrelli E (1997) Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors. J Neurosci 17:4536-4544 (Pubitemid 27246911)
11. Caudle WM, Zhang J (2009) Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol 220:230-233
12. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236-243 (Pubitemid 46654236)
13. Cepeda C, Hurst RS, Altemus KL, Flores-Hernandez J, Calvert CR, Jokel ES, Grandy DK, Low MJ, Rubinstein M, Ariano MA, Levine MS (2001) Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 85:659-670 (Pubitemid 32147768)
14. Corvol JC, Muriel MP, Valjent E, Feger J, Hanoun N, Girault JA, Hirsch EC, Herve D (2004) Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci 24:7007-7014 (Pubitemid 39045457)
15. Crocker AD (1997) The regulation of motor control: an evaluation of the role of dopamine receptors in the substantia nigra. Rev Neurosci 8:55-76 (Pubitemid 27354658)
16. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 54:S21-S23
17. Descarries L, Watkins KC, Garcia S, Bosler O, Doucet G (1996) Dual character, asynaptic and synaptic, of the dopamine innervation in adult rat neostriatum: a quantitative autoradiographic and immunocytochemical analysis. J Comp Neurol 375:167-186 (Pubitemid 26378130)
18. Diaz J, Levesque D, Lammers CH, Griffon N, Martres MP, Schwartz JC, Sokoloff P (1995) Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 65:731-745
19. Evans AH, Lees AJ (2004) Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 17:393-398 (Pubitemid 39071414)
20. Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, Lawrence AD, Lees AJ (2004) Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19:397-405 (Pubitemid 38559642)
21. Fisone G, Hakansson K, Borgkvist A, Santini E (2007) Signaling in the basal ganglia: postsynaptic and presynaptic mechanisms. Physiol Behav 92:8-14 (Pubitemid 47376895)
22. Fulop F, Szatmari I, Vamos E, Zadori D, Toldi J, Vecsei L (2009) Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 16:4828-4842
23. Gardner EL (2011) Addiction and brain reward and antireward pathways. Adv Psychosom Med 30:22-60
24. Gerfen CR, Surmeier DJ (2011) Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34:441-466
25. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P (2003) Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110:1119-1127 (Pubitemid 37271855)
26. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423-428 (Pubitemid 30248740)
27. Girault JA (2012) Integrating neurotransmission in striatal medium spiny neurons. Adv Exp Med Biol 970:407-429
28. Grace AA, Bunney BS (1983) Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-2. Action potential generating mechanisms and morphological correlates. Neuroscience 10:317-331 (Pubitemid 13019571)
29. Grace AA, Bunney BS (1984a) The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4:2877-2890 (Pubitemid 15224432)
30. Grace AA, Bunney BS (1984b) The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4:2866-2876 (Pubitemid 15224431)
31. Graham WC, Robertson RG, Sambrook MA, Crossman AR (1990) Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci 47:PL91-PL97
32. Gregoire L, Rassoulpour A, Guidetti P, Samadi P, Bedard PJ, Izzo E, Schwarcz R, Di Paolo T (2008) Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res 186:161-167 (Pubitemid 350122751)
33. Halpain S, Girault JA, Greengard P (1990) Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature 343:369-372 (Pubitemid 20032854)
34. Harris CA, Miranda AF, Tanguay JJ, Boegman RJ, Beninger RJ, Jhamandas K (1998) Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br J Pharmacol 124:391-399 (Pubitemid 28248031)
35. Hatzipetros T, Yamamoto BK (2006) Dopaminergic and GABAergic modulation of glutamate release from rat subthalamic nucleus efferents to the substantia nigra. Brain Res 1076:60-67 (Pubitemid 43376023)
36. Hemmings HC Jr, Greengard P, Tung HY, Cohen P (1984) DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310:503-505 (Pubitemid 14052413)
37. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463-7473 (Pubitemid 32904945)
38. Kemp JA, Foster AC, Leeson PD, Priestley T, Tridgett R, Iversen LL, Woodruff GN (1988) 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-d-aspartate receptor complex. Proc Natl Acad Sci USA 85:6547-6550
39. Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319-1328 (Pubitemid 19085960)
40. Knyihar-Csillik E, Csillik B, Pakaski M, Krisztin-Peva B, Dobo E, Okuno E, Vecsei L (2004) Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment. Neuroscience 126:899-914 (Pubitemid 38780895)
41. Knyihar-Csillik E, Chadaide Z, Mihaly A, Krisztin-Peva B, Fenyo R, Vecsei L (2006) Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra. Acta Neuropathol 112:127-137
42. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54:1589-1595 (Pubitemid 30226801)
43. Lee do Y, Lee KS, Lee HJ, Noh YH, Kim do H, Lee YJ, Cho SH, Yoon OJ, Lee WB, Kim KY, Chung YH, Kim SS (2008) Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway. Eur J Cell Biol 87:389-397
44. Lee JY, Lee EK, Park SS, Lim JY, Kim HJ, Kim JS, Jeon BS (2009) Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord 24:1803-1810
45. Leon J, Vives F, Gomez I, Camacho E, Gallo MA, Espinosa A, Escames G, Acuna-Castroviejo D (1998) Modulation of rat striatal glutamatergic response in search for new neuroprotective agents: evaluation of melatonin and some kynurenine derivatives. Brain Res Bull 45:525-530 (Pubitemid 28188545)
46. Leonard AS, Hell JW (1997) Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-d-aspartate receptors at different sites. J Biol Chem 272:12107-12115 (Pubitemid 27202791)
47. Lim SY, Evans AH, Miyasaki JM (2008) Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci 1142:85-107
48. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc Natl Acad Sci USA 94:5923-5928 (Pubitemid 27241873)
49. Luchowski P, Luchowska E, Turski WA, Urbanska EM (2002) 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats. Neurosci Lett 330:49-52 (Pubitemid 35245767)
50. Marosi M, Nagy D, Farkas T, Kis Z, Rozsa E, Robotka H, Fulop F, Vecsei L, Toldi J (2010) A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study. J Neural Transm 117:183-188
51. Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, Blandini F (2007) Homocysteine and Parkinson's disease: a dangerous liaison? J Neurol Sci 257:31-37 (Pubitemid 46856499)
52. McRitchie DA, Cartwright HR, Halliday GM (1997) Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp Neurol 144:202-213 (Pubitemid 27149624)
53. Menza M (2000) The personality associated with Parkinson's disease. Curr Psychiatry Rep 2:421-426
54. Meredith GE, Totterdell S, Beales M, Meshul CK (2009) Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol 219:334-340
55. Merino M, Vizuete ML, Cano J, Machado A (1999) The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+. J Neurochem 73:750-757 (Pubitemid 29339850)
56. Miller JM, MacGarvey U, Beal MF (1992) The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations. Neurosci Lett 146:115-118
57. Miranda AF, Boegman RJ, Beninger RJ, Jhamandas K (1997) Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 78:967-975 (Pubitemid 27223703)
58. Misgeld U (2004) Innervation of the substantia nigra. Cell Tissue Res 318:107-114 (Pubitemid 39362631)
59. Miyazaki I, Asanuma M (2008) Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama 62:141-150
60. Morin N, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58:981-986
61. Muller T (2010) Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-l-methionine and related mechanisms. Int Rev Neurobiol 95:49-71
62. Muller T, Kuhn W (2007) Neurotoxicity of levodopa: treatment-associated homocysteine increase. Nat Clin Pract Neurol 3:E1
63. Muller T, Muhlack S (2011) Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients. Mov Disord 26:543-546
64. Muller T, Muhlack S (2012) Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease. Neurosci Lett 521:37-39
65. Muller T, Hefter H, Hueber R, Jost WH, Leenders KL, Odin P, Schwarz J (2004) Is levodopa toxic? J Neurol 251(Suppl 6):VI/44-VI/46
66. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced. Brain Res 451:205-212
67. Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, Saso S (1992) Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42:1702-1706
68. Ouattara B, Belkhir S, Morissette M, Dridi M, Samadi P, Gregoire L, Meltzer LT, Di Paolo T (2009) Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. J Mol Neurosci 38:128-142
69. Paille V, Picconi B, Bagetta V, Ghiglieri V, Sgobio C, Di Filippo M, Viscomi MT, Giampa C, Fusco FR, Gardoni F, Bernardi G, Greengard P, Di Luca M, Calabresi P (2010) Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 30:14182-14193
70. Parkinson J (1817) An essay on the shaking palsy. Sherwood, Neely and Jones, London
71. Pascoli V, Besnard A, Herve D, Pages C, Heck N, Girault JA, Caboche J, Vanhoutte P (2011) Cyclic adenosine monophosphate-independent tyrosine phosphorylation of NR2B mediates cocaine-induced extracellular signal-regulated kinase activation. Biol Psychiatry 69:218-227
72. Pascoli V, Turiault M, Luscher C (2012) Reversal of cocaine-evoked synaptic potentiation resets drug-induced adaptive behaviour. Nature 481:71-75
73. Pezzella FR, Colosimo C, Vanacore N, Di Rezze S, Chianese M, Fabbrini G, Meco G (2005) Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 20:77-81 (Pubitemid 40277510)
74. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 6:501-506 (Pubitemid 36514698)
75. 2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci 24:5283-5291 (Pubitemid 38747668)
76. Picconi B, Bagetta V, Ghiglieri V, Paille V, Di Filippo M, Pendolino V, Tozzi A, Giampa C, Fusco FR, Sgobio C, Calabresi P (2011) Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 134:375-387
77. Picconi B, Piccoli G, Calabresi P (2012) Synaptic dysfunction in Parkinson's disease. Adv Exp Med Biol 970:553-572
78. Rascol O, Lozano A, Stern M, Poewe W (2011) Milestones in Parkinson's disease therapeutics. Mov Disord 26:1072-1082
79. Rassoulpour A, Wu HQ, Ferre S, Schwarcz R (2005) Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem 93:762-765 (Pubitemid 40617635)
80. Rice ME, Patel JC, Cragg SJ (2011) Dopamine release in the basal ganglia. Neuroscience 198:112-137
81. Robelet S, Melon C, Guillet B, Salin P, Kerkerian-Le Goff L (2004) Chronic l-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J Neurosci 20:1255-1266 (Pubitemid 39233578)
82. Robertson RG, Farmery SM, Sambrook MA, Crossman AR (1989) Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res 476:317-322 (Pubitemid 19012600)
83. Rodriguez MC, Obeso JA, Olanow CW (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44:S175-S188
84. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA (2009) Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128-1139
85. Rover S, Cesura AM, Huguenin P, Kettler R, Szente A (1997) Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 40:4378-4385 (Pubitemid 28042317)
86. Schwarcz R (2004) The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 4:12-17 (Pubitemid 38145832)
87. Sgambato V, Pages C, Rogard M, Besson MJ, Caboche J (1998) Extracellular signal-regulated kinase (ERK) controls immediate early gene induction on corticostriatal stimulation. J Neurosci 18:8814-8825 (Pubitemid 28491747)
88. Sgambato-Faure V, Cenci MA (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol 96:69-86
89. Silva-Adaya D, Perez-De La Cruz V, Villeda-Hernandez J, Carrillo-Mora P, Gonzalez-Herrera IG, Garcia E, Colin-Barenque L, Pedraza-Chaverri J, Santamaria A (2011) Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol 33:303-312
90. Spencer AH, Rickards H, Fasano A, Cavanna AE (2011) The prevalence and clinical characteristics of punding in Parkinson's disease. Mov Disord 26:578-586
91. Stone TW (2000) Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 21:149-154 (Pubitemid 30190140)
92. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, Shah L, Wheatley K, Gray R (2008) Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev (2):CD006564
93. Szalardy L, Klivenyi P, Zadori D, Fulop F, Toldi J, Vecsei L (2012) Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Curr Med Chem 19:1899-1920
94. Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol JC, Stipanovich A, Caboche J, Lombroso PJ, Nairn AC, Greengard P, Herve D, Girault JA (2005) Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci USA 102:491-496 (Pubitemid 40116794)
95. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, Lang AE, Miyasaki J (2006) Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67:1254-1257 (Pubitemid 44563838)
96. Wu HQ, Rassoulpour A, Schwarcz R (2002) Effect of systemic l-DOPA administration on extracellular kynurenate levels in the rat striatum. J Neural Transm 109:239-249 (Pubitemid 34251630)
97. Yger M, Girault JA (2011) DARPP-32, Jack of all trades. master of which? Front Behav Neurosci 5:56
98. Zadori D, Ilisz I, Klivenyi P, Szatmari I, Fulop F, Toldi J, Vecsei L, Peter A (2011a) Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog. J Pharm Biomed Anal 55:540-543
99. Zadori D, Klivenyi P, Plangar I, Toldi J, Vecsei L (2011b) Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med 15:701-717
100. Zadori D, Nyiri G, Szonyi A, Szatmari I, Fulop F, Toldi J, Freund TF, Vecsei L, Klivenyi P (2011c) Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. J Neural Transm 118:865-875
101. Zadori D, Klivenyi P, Toldi J, Fulop F, Vecsei L (2012) Kynurenines in Parkinson's disease: therapeutic perspectives. J Neural Transm 119:275-283
102. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, Louie JY, Wu T, Scearce-Levie K, Patrick C, Adame A, Giorgini F, Moussaoui S, Laue G, Rassoulpour A, Flik G, Huang Y, Muchowski JM, Masliah E, Schwarcz R, Muchowski PJ (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145:863-874